Oral Camostat Compared With Standard Supportive Care in Mild-Moderate COVID-19 Patients

Summary

This study will evaluate the efficacy of oral Foipan® (camostat mesilate) compared with the current standard of care in reducing the duration of viral shedding of SARS-CoV-2 virus in patients with mild-moderate COVID-19 disease. Patients will attend 4 study visits over a period of up to 28 days.

Timeline

Start

2020-12-19

Primary completion

2021-05-15

Completion

2021-05-15

Outcome

Missed primary endpoint

registry analysis (superiority test); Camostat Mesilate vs Placebo; p = 0.89; Median Difference (Net) 0.59 (95% CI -8.14 to 9.32); Regression, Linear NCT04524663 ↗

Drugs

Indications